{
    "nct_id": "NCT03770689",
    "official_title": "A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer",
    "inclusion_criteria": "* Participants who have an Eastern Cooperative Oncology Group Performance Status less than or equals to (<=) 1\n* Participants who have histologically confirmed and localized resectable rectal cancer (Stage 3)\n* Participants who received induction chemotherapy are allowed to be enrolled to this study except this induction is resulting in clinical complete response (cCR) or tumor progression\n* Participants who have lower edge of the tumor located in rectum\n* Adequate hematological, hepatic and renal function as defined in the protocol\n* Male participants if they agree to the following during the study intervention period and for at least 12 weeks after the last dose of study intervention\n* Female participants are eligible if not pregnant or breastfeeding\n* Other protocol defined inclusion criteria could apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with history of any other significant medical disease or psychiatric conditions that might in the assessment of the Investigator preclude safe participation in the study\n* Participants with history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the study intervention\n* Unstable cardiovascular function within 6 months prior to enrollment\n* Hypertension uncontrolled by medication (ie, systolic blood pressure >= 150 millimeter of mercury (mmHg) and diastolic blood pressure >= 90 mmHg)\n* Participants with history of other malignant disease within the past 5 years, other than successfully treated basal carcinoma of the skin or carcinoma in situ of the cervix\n* Participants with known human immunodeficiency virus positivity, known active hepatitis (for example, hepatitis B virus or hepatitis C virus), current alcohol abuse, or cirrhosis\n* Participants with ongoing active infection or treatment with a live attenuated vaccine within 4 weeks of dosing\n* Participants with concomitant use of H2-blocker or proton pump inhibitors (PPIs) (or unable to stop at least 5 days prior to the first treatment). Note that calcium carbonate is acceptable\n* Participation in any interventional clinical study within 28 days prior to Screening or during participation in this study\n* Other protocol defined exclusion criteria could apply.",
    "miscellaneous_criteria": ""
}